Auxora
Phase 2- Indications
- Acute pancreatitis, Asparaginase-associated pancreatitis, Acute respiratory distress syndrome
Company intelligence / Profile preview
Vivreon Biosciences
San Diego, California, United Statesventureradar.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Vivreon Biosciences develops novel small molecule therapies targeting the CRAC channel to treat chronic inflammatory and neurodegenerative diseases. Their lead programs are in preclinical stages with a unique mechanism aiming to protect healthy tissue while managing inflammation. No clinical results have been published yet.
- Therapeutic areas
- GastroenterologyImmunologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Vivreon Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vivreon Biosciences.